Comparative Pharmacology
Head-to-head clinical analysis: MAXALT MLT versus TRIAD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXALT MLT versus TRIAD.
MAXALT-MLT vs TRIAD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial arteries and inhibits trigeminal nerve activation.
Triad is a combination of three antibiotics: amoxicillin, metronidazole, and tetracycline. Amoxicillin inhibits bacterial cell wall synthesis. Metronidazole disrupts bacterial DNA synthesis via reduction to toxic metabolites. Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
10 mg orally as a single dose; maximum 30 mg in 24 hours. Administer at onset of migraine; do not use for prophylaxis.
Not applicable. TRIAD is not a recognized drug; no standard dosing exists.
None Documented
None Documented
Terminal elimination half-life of approximately 2-3 hours; clinical context: short half-life supports acute migraine treatment with rapid offset.
Terminal t1/2 = 12–15 hours; prolonged to 24–36 hours in hepatic impairment.
Primarily hepatic metabolism; ~14% excreted unchanged in urine, ~76% as metabolites in feces via bile, total renal excretion of parent and metabolites ~40%.
Renal: 30% unchanged; Biliary/fecal: 70% as metabolites.
Category C
Category C
Antimigraine Agent
Antimigraine Agent